Here are two key new trial-data disclosures from the annual AASLD The Liver Meeting® 2025 (Washington DC) for Day #1, 11/07/2025 —
1. Akero Therapeutics — Data from the Phase 2b “SYMMETRY” & “HARMONY” trials of Efruxifermin in MASLD/MASH
- Akero announced new analyses from the SYMMETRY (F4c compensated-cirrhosis) and HARMONY (F2-F3) trials.
- Highlights:
- In SYMMETRY (96-week), efruxifermin was associated with statistically significant improvements in non‐invasive markers of fibrosis, and reductions in risk of clinically significant portal hypertension (CSPH) in F4c MASH.
- In HARMONY, AI-powered digital pathology analysis reinforced conventional pathology findings of fibrosis improvement in F2/F3 MASH.
2. Madrigal Pharmaceuticals — Presentations from the Phase 3 MAESTRO-NAFLD-1 trial of Resmetirom (branded “Rezdiffra®”) in MASH and cirrhosis
- Madrigal announced multiple data presentations at AASLD: biomarker, imaging, quality‐of-life data from the open-label compensated MASH cirrhosis (F4c) arm of MAESTRO-NAFLD-1.
- Notable abstracts include:
- “Two-Year Time Course of Biomarker and Imaging Responses in Well-Compensated MASH Cirrhosis” (Abstract #0167)
- “Improvement in Health‐Related Quality of Life in Non-Cirrhotic & Cirrhotic Patients with MASLD treated with Resmetirom” (Abstract #0181)
- Poster: “Analysis of Biomarkers PRO-C3 and ELF Components in Baseline MASH/MASLD & MASH Cirrhosis Patients; Correlations Between Change in PRO-C3 and ELF in Resmetirom-Treated Patients” (Abstract #4074)